BIOMEDTECHNOLOGYHOLDINGSLIMITED目前是深圳准肠康生物医学科技有限公司直接控股股东,持股比例为100%,是无锡准肠康生物医学科技有限公司直接控股股东,持股比例为70%;目前BIOMEDTECHNOLOGYHOLDINGSLIMITED投资深圳准肠康生物医学科技有限公司最终收益股份为100%,投资无锡准肠康生物医学科技有限公司最终收益股份为70%;二、BIOMED...
商标名称 生物医学科技控股有限公司 BIOMED TECHNOLOGY HOLDINGS LIMITED 国际分类 第05类-医药 商标状态 等待实质审查 申请/注册号 70712872 申请日期 2023-04-06 申请人名称(中文) 生物医学科技控股有限公司 申请人名称(英文) - 申请人地址(中文) 香港新界沙田香港科學園科技大道西16號3樓311-312室 申请人地址(英...
香港- Media OutReach Newswire - 2024年4月26日 - 香港中文大学教授和校友创办的初创公司生物医学科技控股有限公司(BioMed Technology Holdings Limited)(下称「BioMed」)宣布获得中大创新有限公司(CUHK Innovation Limited)(下称「中大创新」)的投资。 中大创新宣布投资BioMed,为其成立后第一项投资项目。 图为BioMed 行...
企业介绍 产品与服务 新闻稿中心 资源库 联系我们 搜索 BioMed Technology Holdings Limited 医疗健康 企业新闻室
简介:生物医学科技控股有限公司,成立于2018年,位于香港特别行政区,是一家以从事照片洗印服务为主的企业。企业已于2024年完成了Pre-A轮。通过天眼查大数据分析,生物医学科技控股有限公司共对外投资了3家企业;知识产权方面有商标信息17条,专利信息1条,著作权信息1条。
the expandability of platform technology application scenarios which generate impactful values and bring us new value growth points with minimal marginal investment. Representative projects include HBM Alpha Therapeutics, in partnership with Boston Children's Hospital, and Shanghai NK Cell Technology Limited...
This study was supported by the National Natural Science Foundation of China (NO. 81903384) and the Suzhou Science and Technology Development Plan (SKY2023041), and Youth Technology and Science Projects of Suzhou Vocational Health College (NO. SZWZY202216). The funders had no role in the study...
Another incubation program, Shanghai NK Cell Technology Limited, completed its A round financing and raised a fund over RMB100 million to deepen its efforts in cutting-edge NK cell therapeutics. Looking ahead to 2023, HBM will continue to focus on global innovation and cooperation, taking its ...
The focus now turns towards leveraging our unique, globally patent protected technology platforms and industry experience in order to promote the R&D and commercialization of our differentiated portfolio. We will continue to focus on the clinical-stage products that are expected to fill the gap in ...
bstsx blackrock technology opportunities svc 61.04 +1.75% lglfx lord abbett growth leaders fund 39.63 +1.75% bgsrx blackrock technology opportunities fund 59.46 +1.75% lglox lord abbett growth leaders fund 40.36 +1.74% lglvx lord abbett growth leaders fund 40.36 +1.74% ...